BioSpace News Archive

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, announced the Company will release its fourth quarter 2020 results before the market opens on Wednesday, March 10, 2021, to be followed by a conference call at 8:30 a.m. (Eastern Time)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference.

Viral inactivation kit is used to avoid viruses in a given sample from contaminating the target substance, either by entirely killing viruses or by making them non-infectious.

The growth of the global immunofluorescence assay market is ascribed to the rising prevalence of various chronic illnesses.

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference

Patient group EGFR Resisters and LUNGevity Foundation today announced the 2021 recipients of the first EGFR Resisters/LUNGevity Lung Cancer Research Award.

SyBridge Technologies (“SyBridge) a global technological leader in the tooling and mold industry, announced today that its subsidiary Concours Technologies (“Concours”) has completed the acquisition of Active Industrial Solutions, Inc. and Active Industrial Solutions Tennessee, Inc. (collectively “AIS”).

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers.

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX Venture: IPA) announced preliminary, preclinical data in hamsters of IPA’s proprietary TATX-03 PolyTope antibody cocktail program against SARS-CoV-2, the virus that causes COVID-19 disease.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, and Sandip Kapadia, Chief Financial Officer of Intercept, will present at the SVB Leerink 10th Annual Global Healthcare Conference